{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:58:51Z","timestamp":1777111131380,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key R&D Program of Shandong Province","award":["2020RKB14165"],"award-info":[{"award-number":["2020RKB14165"]}]},{"name":"Shandong Province Adverse Drug Reaction Monitoring Center","award":["DRUG-2024-SDADR-019"],"award-info":[{"award-number":["DRUG-2024-SDADR-019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23424-x","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T23:13:38Z","timestamp":1763075618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacovigilance analysis of myopathy associated with azoles and nonstatins interactions based on US FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Shen\u2019ao","family":"Jing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan\u2019nan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang\u2019dong","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"6","key":"23424_CR1","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1586\/14787210.2015.1032939","volume":"13","author":"D Allen","year":"2015","unstructured":"Allen, D. et al. Azole antifungals: 35 years of invasive fungal infection management. Expert Rev. Anti Infect. Ther. 13(6), 787\u2013798. https:\/\/doi.org\/10.1586\/14787210.2015.1032939 (2015).","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"3","key":"23424_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/17425255.2023.2203860","volume":"19","author":"M Biswas","year":"2023","unstructured":"Biswas, M. et al. Azole antifungals and inter-individual differences in drug metabolism: The role of pharmacogenomics and precision medicine. Expert Opin. Drug Metab. Toxicol. 19(3), 165\u2013174. https:\/\/doi.org\/10.1080\/17425255.2023.2203860 (2023).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"8","key":"23424_CR3","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","volume":"79","author":"LL Benitez","year":"2019","unstructured":"Benitez, L. L. & Carver, P. L. Adverse effects associated with long-term administration of azole antifungal agents. Drugs 79(8), 833\u2013853. https:\/\/doi.org\/10.1007\/s40265-019-01127-8 (2019).","journal-title":"Drugs"},{"issue":"2","key":"23424_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1055\/a-1488-6912","volume":"161","author":"J Steinmeyer","year":"2023","unstructured":"Steinmeyer, J. & Flechtenmacher, J. Drug-induced myopathies. Arzneimittelinduzierte Myopathien. Z. Orthop. Unfall. 161(2), 175\u2013181. https:\/\/doi.org\/10.1055\/a-1488-6912 (2023).","journal-title":"Z. Orthop. Unfall."},{"issue":"5","key":"23424_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2174\/1389200222666210114122729","volume":"22","author":"R Balasubramanian","year":"2021","unstructured":"Balasubramanian, R. & Maideen, N. M. P. HMG-CoA reductase Inhibitors (Statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-an overview. Curr. Drug Metab. 22(5), 328\u2013341. https:\/\/doi.org\/10.2174\/1389200222666210114122729 (2021).","journal-title":"Curr. Drug Metab."},{"issue":"1","key":"23424_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2174\/1574886318666230227143627","volume":"19","author":"R Kammoun","year":"2024","unstructured":"Kammoun, R. et al. Statin associated muscular adverse effects. Curr. Drug Saf. 19(1), 114\u2013116. https:\/\/doi.org\/10.2174\/1574886318666230227143627 (2024).","journal-title":"Curr. Drug Saf."},{"key":"23424_CR7","doi-asserted-by":"publisher","DOI":"10.2174\/0118715303324204240905111835","author":"J Li","year":"2024","unstructured":"Li, J. et al. Safety profile of statins for post-marketing adverse cardiovascular events: A real-world pharmacovigilance analysis. Endocr. Metab. Immune Disord. Drug Targets https:\/\/doi.org\/10.2174\/0118715303324204240905111835 (2024).","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"issue":"3","key":"23424_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/14740338.2024.2424438","volume":"24","author":"H Wan","year":"2025","unstructured":"Wan, H. et al. Real-world safety evaluation of atorvastatin: Insights from the US FDA adverse event reporting system (FAERS). Expert Opin. Drug Saf. 24(3), 305\u2013314 (2025).","journal-title":"Expert Opin. Drug Saf."},{"issue":"2","key":"23424_CR9","doi-asserted-by":"publisher","first-page":"e3998","DOI":"10.7759\/cureus.3998","volume":"11","author":"M Soliman","year":"2019","unstructured":"Soliman, M. et al. Voriconazole-induced myositis in a double lung transplant recipient. Cureus 11(2), e3998. https:\/\/doi.org\/10.7759\/cureus.3998 (2019).","journal-title":"Cureus"},{"issue":"7","key":"23424_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/RHU.0b013e318188bea7","volume":"15","author":"VK Shanmugam","year":"2009","unstructured":"Shanmugam, V. K. et al. Voriconazole-associated myositis. J. Clin. Rheumatol. 15(7), 350\u2013353. https:\/\/doi.org\/10.1097\/RHU.0b013e318188bea7 (2009).","journal-title":"J. Clin. Rheumatol."},{"issue":"3","key":"23424_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11926-010-0104-3","volume":"12","author":"R Valiyil","year":"2010","unstructured":"Valiyil, R. & Christopher-Stine, L. Drug-related myopathies of which the clinician should be aware. Curr. Rheumatol. Rep. 12(3), 213\u2013220. https:\/\/doi.org\/10.1007\/s11926-010-0104-3 (2010).","journal-title":"Curr. Rheumatol. Rep."},{"issue":"10300","key":"23424_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0140-6736(21)00879-5","volume":"398","author":"N Pallet","year":"2021","unstructured":"Pallet, N. & Loriot, M. A. Voriconazole pharmacogenetics. Lancet 398(10300), 578. https:\/\/doi.org\/10.1016\/S0140-6736(21)00879-5 (2021) (PMID: 34391494).","journal-title":"Lancet"},{"issue":"1","key":"23424_CR13","doi-asserted-by":"publisher","first-page":"12519","DOI":"10.1038\/s41598-024-63504-y","volume":"14","author":"H Kato","year":"2024","unstructured":"Kato, H. et al. Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database. Sci. Rep. 14(1), 12519 (2024).","journal-title":"Sci. Rep."},{"key":"23424_CR14","doi-asserted-by":"publisher","first-page":"1292163","DOI":"10.3389\/fphar.2024.1292163","volume":"15","author":"BN Huo","year":"2024","unstructured":"Huo, B. N. et al. Clinical drug interactions between voriconazole and 38 other drugs: A retrospective analysis of adverse events. Front. Pharmacol. 15, 1292163 (2024).","journal-title":"Front. Pharmacol."},{"issue":"10","key":"23424_CR15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1080\/14740338.2024.2391492","volume":"23","author":"J Yun","year":"2024","unstructured":"Yun, J., Wang, Z. & Liu, W. Voriconazole-induced central nervous system toxicity: A pharmacovigilance study based on FDA adverse event reporting system (FAERS) database. Expert Opin. Drug Saf. 23(10), 1309\u20131316 (2024).","journal-title":"Expert Opin. Drug Saf."},{"key":"23424_CR16","doi-asserted-by":"publisher","first-page":"1255918","DOI":"10.3389\/fphar.2024.1255918","volume":"15","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Evaluating cardiac disorders associated with triazole antifungal agents based on the US Food and drug administration adverse event reporting system database. Front. Pharmacol. 15, 1255918 (2024).","journal-title":"Front. Pharmacol."},{"issue":"8","key":"23424_CR17","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/pharmaceutics12080762","volume":"12","author":"Y Noguchi","year":"2020","unstructured":"Noguchi, Y., Tachi, T. & Teramachi, H. Subset analysis for screening drug-drug interaction signal using pharmacovigilance database. Pharmaceutics 12(8), 762. https:\/\/doi.org\/10.3390\/pharmaceutics12080762 (2020).","journal-title":"Pharmaceutics"},{"issue":"11","key":"23424_CR18","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","volume":"87","author":"R B\u00f6hm","year":"2021","unstructured":"B\u00f6hm, R. et al. Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. Br. J. Clin. Pharmacol. 87(11), 4421\u20134431. https:\/\/doi.org\/10.1111\/bcp.14868 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"23424_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","volume":"30","author":"R B\u00f6hm","year":"2012","unstructured":"B\u00f6hm, R. et al. OpenVigil\u2013free eyeballs on AERS pharmacovigilance data. Nat. Biotechnol. 30(2), 137\u2013138. https:\/\/doi.org\/10.1038\/nbt.2113 (2012).","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"23424_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40264-014-0187-2","volume":"37","author":"H G\u00e9niaux","year":"2014","unstructured":"G\u00e9niaux, H. et al. Performance of the standardised MedDRA\u00ae queries for case retrieval in the French spontaneous reporting database. Drug Saf. 37(7), 537\u2013542. https:\/\/doi.org\/10.1007\/s40264-014-0187-2 (2014).","journal-title":"Drug Saf."},{"issue":"4","key":"23424_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1345\/aph.1H423","volume":"41","author":"JR Horn","year":"2007","unstructured":"Horn, J. R., Hansten, P. D. & Chan, L. N. Proposal for a new tool to evaluate drug interaction cases. Ann. Pharmacother. 41(4), 674\u2013680. https:\/\/doi.org\/10.1345\/aph.1H423 (2007).","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"23424_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek, E. P. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug Saf. 11(1), 3\u201310 (2002).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"8","key":"23424_CR23","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40264-022-01200-4","volume":"45","author":"L Villa-Zapata","year":"2022","unstructured":"Villa-Zapata, L. et al. A Disproportionality analysis of drug-drug interactions of tizanidine and CYP1A2 inhibitors from the FDA adverse event reporting system (FAERS). Drug Saf. 45(8), 863\u2013871 (2022).","journal-title":"Drug Saf."},{"issue":"6","key":"23424_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/pds.885","volume":"12","author":"JS Almenoff","year":"2003","unstructured":"Almenoff, J. S. et al. Disproportionality analysis using empirical Bayes data mining: A tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol. Drug Saf. 12(6), 517\u2013521 (2003).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"23424_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n, G. N., Hopstadius, J. & Bate, A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat. Methods Med. Res. 22(1), 57\u201369 (2013).","journal-title":"Stat. Methods Med. Res."},{"issue":"1","key":"23424_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","volume":"7","author":"Y Zhai","year":"2019","unstructured":"Zhai, Y. et al. Endocrine toxicity of immune checkpoint inhibitors: A real-world study leveraging US food and drug administration adverse events reporting system. J. Immunother. Cancer 7(1), 286 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"23424_CR27","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3389\/fphar.2019.01319","volume":"10","author":"Y Noguchi","year":"2019","unstructured":"Noguchi, Y., Tachi, T. & Teramachi, H. Review of statistical methodologies for detecting drug-drug interactions using spontaneous reporting systems. Front. Pharmacol. 10, 1319. https:\/\/doi.org\/10.3389\/fphar.2019.01319 (2019).","journal-title":"Front. Pharmacol."},{"key":"23424_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.18433\/jpps32867","volume":"25","author":"Z Yu","year":"2022","unstructured":"Yu, Z. & Liao, X. Torsade de pointes\/QT prolongation associated with antifungal triazoles: A pharmacovigilance study based on the US FDA adverse event reporting system(FAERS). J. Pharm. Pharm. Sci. 25, 237\u2013243. https:\/\/doi.org\/10.18433\/jpps32867 (2022).","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"1","key":"23424_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek, E. P. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug Saf. 11(1), 3\u201310. https:\/\/doi.org\/10.1002\/pds.668 (2002).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"23424_CR30","doi-asserted-by":"crossref","unstructured":"DuMouchel, W. & Pregibon, D. Empirical Bayes Screening for Multi-item Associations. In Proceedings of the Seventh ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, KDD 01, 67\u201376 (ACM, 2001).","DOI":"10.1145\/502512.502526"},{"key":"23424_CR31","doi-asserted-by":"publisher","unstructured":"Honma, T., Onda, K., & Masuyama, K.  Drug-drug interaction assessment based on a large-scale spontaneous reporting system for hepato- and renal-toxicity, and thrombocytopenia with concomitant low-dose methotrexate and analgesics use. BMC pharmacology & toxicology, 25(1), 13 https:\/\/doi.org\/10.1186\/s40360-024-00738-6 (2024).","DOI":"10.1186\/s40360-024-00738-6"},{"issue":"16","key":"23424_CR32","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/sim.3247","volume":"27","author":"GN Nor\u00e9n","year":"2008","unstructured":"Nor\u00e9n, G. N. et al. A statistical methodology for drug-drug interaction surveillance. Stat. Med. 27(16), 3057\u20133070 (2008).","journal-title":"Stat. Med."},{"issue":"6","key":"23424_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M. et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): Development and statement. Drug Saf. 47(6), 575\u2013584. https:\/\/doi.org\/10.1007\/s40264-024-01421-9 (2024).","journal-title":"Drug Saf."},{"issue":"2","key":"23424_CR34","first-page":"116","volume":"36","author":"Z Zhiyu","year":"2018","unstructured":"Zhiyu, Z. & Dongliang, Li. A case of rhabdomyolysis in a patient with liver failure induced by the interaction between voriconazole and esomeprazole. Chin. J. Infect. Dis. 36(2), 116\u2013117 (2018).","journal-title":"Chin. J. Infect. Dis."},{"issue":"11","key":"23424_CR35","first-page":"686","volume":"21","author":"Qu Caihong","year":"2011","unstructured":"Caihong, Qu. & Ziying, L. Rhabdomyolysis in a patient with hepatitis b cirrhosis and pulmonary invasive fungal infection induced by the combination of voriconazole and esomeprazole. Pharm. Today 21(11), 686\u2013688 (2011).","journal-title":"Pharm. Today"},{"issue":"6","key":"23424_CR36","first-page":"374","volume":"13","author":"Qu Caihong","year":"2011","unstructured":"Caihong, Qu. & Xiaoyan, Li. Possible adverse drug interaction between voriconazole and omeprazole leading to myopathy and liver function deterioration. Adv. Drug React. J. 13(6), 374\u2013377 (2011).","journal-title":"Adv. Drug React. J."},{"issue":"1","key":"23424_CR37","first-page":"50","volume":"25","author":"Li Mei","year":"2017","unstructured":"Mei, Li. et al. A case of rhabdomyolysis induced by voriconazole in the treatment of severe hepatitis with pulmonary fungal infection. Chin. J. Hepatol. 25(1), 50\u201351 (2017).","journal-title":"Chin. J. Hepatol."},{"issue":"12","key":"23424_CR38","first-page":"1081","volume":"42","author":"Z Cejun","year":"2017","unstructured":"Cejun, Z. et al. Report of 3 cases of rare adverse reactions to voriconazole and literature review. Chin. J. Antibiot. 42(12), 1081\u20131085 (2017).","journal-title":"Chin. J. Antibiot."},{"issue":"9","key":"23424_CR39","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.26355\/eurrev_202305_32288","volume":"27","author":"F Su","year":"2023","unstructured":"Su, F. et al. A case of drug-induced myopathy in alcoholic cirrhosis caused by voriconazole. Eur. Rev. Med. Pharmacol. Sci. 27(9), 3833\u20133836. https:\/\/doi.org\/10.26355\/eurrev_202305_32288 (2023).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"5","key":"23424_CR40","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1097\/MPH.0000000000001022","volume":"40","author":"E Pekpak","year":"2018","unstructured":"Pekpak, E. et al. Toxicity of vincristine combined with posaconazole in children with acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 40(5), e309\u2013e310. https:\/\/doi.org\/10.1097\/MPH.0000000000001022 (2018).","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"1","key":"23424_CR41","doi-asserted-by":"publisher","first-page":"232470961769074","DOI":"10.1177\/2324709617690747","volume":"5","author":"MD Mody","year":"2017","unstructured":"Mody, M. D. et al. Rhabdomyolysis following initiation of posaconazole use for antifungal prophylaxis in a patient with relapsed acute myeloid leukemia: A case report. J. Investig. Med. High Impact Case Rep. 5(1), 2324709617690747. https:\/\/doi.org\/10.1177\/2324709617690747 (2017).","journal-title":"J. Investig. Med. High Impact Case Rep."},{"issue":"3","key":"23424_CR42","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000077429","volume":"71","author":"M Ferrari","year":"2004","unstructured":"Ferrari, M., Bodini, I. & Lo, C. V. Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis. Respiration 71(3), 289\u2013291. https:\/\/doi.org\/10.1159\/000077429 (2004).","journal-title":"Respiration"},{"key":"23424_CR43","doi-asserted-by":"publisher","first-page":"7323755","DOI":"10.1155\/2022\/7323755","volume":"2022","author":"S Happaerts","year":"2022","unstructured":"Happaerts, S. et al. Azole-induced myositis after combined lung-liver transplantation. Case Rep. Transplant. 2022, 7323755. https:\/\/doi.org\/10.1155\/2022\/7323755 (2022).","journal-title":"Case Rep. Transplant."},{"issue":"3","key":"23424_CR44","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2478\/acph-2013-0022","volume":"63","author":"A Causevic-Ramosevac","year":"2013","unstructured":"Causevic-Ramosevac, A. & Semiz, S. Drug interactions with statins. Acta Pharm. 63(3), 277\u2013293. https:\/\/doi.org\/10.2478\/acph-2013-0022 (2013).","journal-title":"Acta Pharm."},{"issue":"7","key":"23424_CR45","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1080\/23744235.2017.1418531","volume":"50","author":"MT Rosanova","year":"2018","unstructured":"Rosanova, M. T. et al. Efficacy and safety of voriconazole in immunocompromised patients: Systematic review and meta-analysis. Infect. Dis. (Lond.) 50(7), 489\u2013494. https:\/\/doi.org\/10.1080\/23744235.2017.1418531 (2018).","journal-title":"Infect. Dis. (Lond.)"},{"issue":"11","key":"23424_CR46","doi-asserted-by":"publisher","first-page":"e3606","DOI":"10.1093\/cid\/ciaa1065","volume":"73","author":"M Bartoletti","year":"2021","unstructured":"Bartoletti, M. et al. Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: A prospective study. Clin. Infect. Dis. 73(11), e3606\u2013e3614. https:\/\/doi.org\/10.1093\/cid\/ciaa1065 (2021).","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"23424_CR47","doi-asserted-by":"publisher","first-page":"e2017652","DOI":"10.1001\/jamanetworkopen.2020.17652","volume":"3","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing hematopoietic stem cell transplantation: A systematic review and network meta-analysis. JAMA Netw. Open. 3(10), e2017652. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.17652 (2020).","journal-title":"JAMA Netw. Open."},{"issue":"Suppl 7","key":"23424_CR48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/imj.15591","volume":"51","author":"AP Douglas","year":"2021","unstructured":"Douglas, A. P. et al. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Intern. Med. J. 51(Suppl 7), 143\u2013176. https:\/\/doi.org\/10.1111\/imj.15591 (2021).","journal-title":"Intern. Med. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23424-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23424-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23424-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T23:13:40Z","timestamp":1763075620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23424-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23424"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23424-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethic approval was not sought from the Institutional Review Board as the study only involved the analysis of data obtained from a public database. Informed consent to participate was not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"39870"}}